Detailed analysis of the SURMOUNT-1 phase 3 tirzepatide trial — 72-week efficacy data, ~20.9% mean weight reduction, safety profile, and 2026 research implications.
Detailed analysis of the SURMOUNT-1 phase 3 tirzepatide trial — 72-week efficacy data, ~20.9% mean weight reduction, safety profile, and 2026 research implications.